Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
Cerevel Therapeutics (NASDAQ:CERE) announced participation in three virtual investor conferences in November 2020. The events include:
- Guggenheim Healthcare Talks on November 16, focusing on neuro/immunology.
- Stifel 2020 Virtual Healthcare Conference on November 17, featuring a fireside chat at 10:00 a.m. EST.
- Jefferies Virtual London Healthcare Conference on November 18-19, with a chat at 10:50 a.m. EST on November 18.
Live webcasts will be available on the company's investor relations page.
- None.
- None.
BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming virtual investor conferences during the month of November.
| Event: | Guggenheim Healthcare Talks | 2nd Annual Neuro/Immunology Day |
| Date: | November 16, 2020 |
| Format: | One-on-one investor meetings |
| Event: | Stifel 2020 Virtual Healthcare Conference |
| Date: | November 17, 2020 |
| Format: | Fireside chat and one-on-one investor meetings |
| Time: | 10:00 a.m. EST |
| Event: | Jefferies Virtual London Healthcare Conference |
| Date: | November 18-19, 2020 |
| Format: | Fireside chat and one-on-one investor meetings |
| Time: | 10:50 a.m. EST/3:50 p.m. GMT on November 18, 2020 |
Live audio webcasts of the virtual conference fireside chats with Cerevel Therapeutics’ Chairperson and Chief Executive Officer Tony Coles, M.D., can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the company’s website for approximately 90 days.
About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit www.cerevel.com.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Rachel Eides
W2O pure
reides@purecommunications.com
Investor Contact:
Matthew Calistri
Cerevel Therapeutics
matthew.calistri@cerevel.com
FAQ
What investor conferences will Cerevel Therapeutics participate in November 2020?
What is the date and format for the Stifel 2020 Virtual Healthcare Conference?
When is the Jefferies Virtual London Healthcare Conference taking place?
How can I access the live webcasts for Cerevel Therapeutics' conferences?
